Adverum Biotechnologies reported a net loss of $15.7 million, or $0.25 per share, in the fourth quarter of 2018 compared with a net loss of $14.8 million, or $0.32 per share, in 2017’s fourth quarter, according to a press release.
General and administrative expenses increased from $4 million in 2017’s final quarter to $5.2 million, while research and development costs decreased from $12 million to $11.6 million.
The company posted collaboration and license revenue of $0.1 million for the quarter compared with $0.5 million a year ago.
For the full (Read more...)
Uncategorized